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Arf encodes an important tumor suppressor, p19Arf, which also plays a critical role to control hyperplasia
in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and
display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic
primary vitreous (PHPV). In this report, we characterize p19Arf expression in perivascular cells that
normally populate the primary vitreous and express the Arf promoter. Using a new ex vivo model, we
show that these cells respond to exogenous Tgfb, despite being isolated at a time when Tgfb has already
turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in
S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfrb
as expression of Arf represses expression of Pdgfrb mRNA and protein to approximately 60%. p53 is not
required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfrb protein as
ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon
treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identiﬁed to be
regulated by p19Arf does not depend on p53 while the expression of the primary transcript does require
p53. These data corroborate that, as in vivo, p19Arf functions to inhibit PDGF-B driven proliferation ex vivo.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During mammalian eye development, the hyaloid vascular
system (HVS) in the primary vitreous provides nutrients to foster
lens and retina development. This vasculature consists of the hya-
loid artery, which feeds the vasa hyaloidea propria (VHP) and tunica
vasculosa lentis (TVL) (Goldberg, 1997; Ito and Yoshioka, 1999). To
achieve optimal vision, this fully formed vasculature regresses in
later stages of eye development, resulting in the avascular and
largely acellular secondary vitreous. Defects in HVS regression and
primary vitreous maturation lead to ocular disease in children. This
disease, variously known as either persistent hyperplastic primary
vitreous (PHPV) or persistent fetal vasculature (PFV) (Goldberg,
1997; Haddad et al., 1978) covers a wide spectrum of severity
from mere remnants of the hyaloid artery stalk to cellular hyper-
plasia leading to erosion of the lens capsule posteriorly and
dysplasia and tractional detachment of the retina, leading to
blindness (Goldberg, 1997; Haddad et al., 1978). Currently, thera-
peutic interventions largely hinge on surgical interventions to try to.edu (S.X. Skapek).
Ltd. This is an open access article upreserve or restore vision or remove a severely diseased eye (Hunt
et al., 2005; Pollard, 1997).
The underlying pathogenetic mechanisms are likely to vary with
disease severity, and this notion is supported in pre-clinical mouse
models of the disease. These mechanisms can largely be divided
into fundamental defects in pro-apoptotic processes needed to
clear the cells from the vitreous and defects in processes that check
hyperplastic expansion of primary vitreous cells e quite literally
paralleling the two descriptors for the disease: PFV and PHPV. The
former is reﬂected in mouse models with germ-line destruction of
the p53 tumor suppressor gene (Ikeda et al., 1999) or angiopoietin-
2 (Gale et al., 2002; Hackett et al., 2002) or in mice lacking
macrophage-like hyalocytes (Lang and Bishop, 1993) or the WNT7B
signals needed for them to exert cytotoxic effects on endothelial
cells in the HVS (Lobov et al., 2005). In contrast, deregulated
vascular endothelial growth factor (VEGF) (Mitchell et al., 1998;
Rutland et al., 2007) or platelet-derived growth factor-B (PDGF-B)
(Lei et al., 2010; Niklasson et al., 2010) support the hyperplastic
expansion of primary vitreous cells and PHPV-like phenotype. Anti-
proliferative factors have also been implicated. In particular, loss of
the Arf tumor suppressor gene leads to hyperplasia of Pdgfrb-
expressing perivascular cells that normally ﬂank the hyaloid artery
(McKeller et al., 2002; Widau et al., 2012). The phenotype of Arf/nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. p19Arf is expressed in the primary vitreous and responds to exogenous Tgfb. A)
Representative photomicrograph image of developing vitreous at E13.5 from ArfGfp/Gfp
mouse. Gfp expression, as a marker for Arf promoter activation, is robustly detected in
cells of the primary vitreous space. B) Relative expression of Gfp as a surrogate marker
for exon1b measured by qRT-PCR. PVCs were treated with 5 ng/mL Tgfb1 or 4 mM HCl
vehicle control. RNA was extracted 48 h after treatment. Gfp expression is normalized
to Gapdh control (* ¼ p < 0.02).
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retrolental, ﬁbrovascular mass that erodes the lens capsule and
distorts the retina; and dense lens opacity resulting in blindness
(Martin et al., 2004; McKeller et al., 2002). Although Arf/ mice
develop bilateral, severe eye disease, contrasting the typical clinical
presentation, loss of Arf in just a subset of primary vitreous cells
through somatic mosaic deletion leads to a more variable pheno-
type with incomplete disease penetrance e better mimicking the
clinical scenario (Mary-Sinclair et al., 2014).
Because Arf is normally expressed in perivascular cells of the
primary vitreous, it represents an essential component of normal
mouse eye development (Martin et al., 2004; McKeller et al., 2002;
Silva et al., 2005). Arf encodes p19Arf, a nuclear protein best known
for its capacity to negatively regulate Mdm2, thereby stabilizing
(and activating) p53 (Honda and Yasuda, 1999; Weber et al., 1999).
A linear pathway from p19Arf to p53 cannot fully account for the
developmental effects, though, because p53 deﬁcient mice usually
have normal eyes, whereas Arf loss leads to PHPV in a variety of
pure and mixed mouse strains (Ikeda et al., 1999; McKeller et al.,
2002; Reichel et al., 1998). Clues to the biochemical effects of
p19Arf ﬁrst came from genetic studies showing that the hyperplastic
phenotype is ameliorated in Arf/, Pdgfrb/ embryos (Widau
et al., 2012), and p19Arf expression correlates with lower expres-
sion of Pdgfrb in the developing eye, and in cultured mouse em-
bryonic ﬁbroblasts (MEFs) (Silva et al., 2005; Thornton et al., 2007;
Widau et al., 2012). More detailed mechanistic studies e also
conducted in MEFs and 10T1/2 ﬁbroblasts e demonstrated that
p19Arf expression can block Pdgfrb mRNA transcription in a p53-
dependent way and Pdgfrb protein translation independently of
p53 (Widau et al., 2012). Finally, miR34a, a microRNA known to be
controlled by p53, is also induced by p19Arf and is required for p53-
indendent translational repression of Pdgfrb (Iqbal et al., 2014a).
Though this detailed molecular mechanism explains the ocular
phenotype in the absence of Arf, it is important to recognize that
the experiments were conducted in mouse ﬁbroblasts, whereas the
cells that normally express p19Arf are pericyte-like cells derived
from the neural crest (Silva et al., 2005; Zheng et al., 2010). In this
report, we functionally characterize and conﬁrm aspects of Arf
biology previously deﬁned in other cell types and in vivo in an
ex vivo cell culture model that represents the ﬁrst model in which
the Arf promoter is normally active.
2. Results
To verify that the aforementioned molecular and genetic
pathway is relevant to the cells normally expressing Arf, we took
advantage of primary cultures of primary vitreous cells (PVCs) that
we puriﬁed by ﬂow cytometry based on expression of a Gfp re-
porter in ArfGfp/Gfp (functionally, Arf/) animals (Iqbal et al., 2014b).
We previously characterized the PVCs by global gene expression
analysis that highlighted, among other things, their pericyte-like
nature (Iqbal et al., 2014b). These cells are readily apparent as
early as embryonic day (E) 12.5 (Martin et al., 2004; McKeller et al.,
2002; Silva et al., 2005) and dramatically increase in number in the
primary vitreous space by E13.5 (Silva et al., 2005) and Fig. 1A.
Several pieces of data indicate that Tgfb2 is required for Arf in-
duction in the primary vitreous. First, Tgfb2/ mice have a variety
of developmental defects, including primary vitreous hyperplasia
(Saika et al., 2001; Sanford et al., 1997), and this correlates with
decreased expression of p19Arf (Freeman-Anderson et al., 2009).
Second, transgenic expression of Tgfb1 driven from the a-crystallin
promoter can correct the primary vitreous hyperplasia in Tgfb2/
mouse embryos, but not in Arf/ embryos, which indicates that
p19Arf is needed for the anti-proliferative effects of Tgfb in the eye
(Zheng et al., 2010). Dual immunoﬂuorescence staining showsp19Arf and the Tgfb receptor TbrII to be coexpressed, suggesting that
this protein signals to induce Arf directly (Freeman-Anderson et al.,
2009). This was conﬁrmed to be true in MEFs and 10T1/2 cells:
exogenous Tgfb1, 2, or 3 increases Smad2/3 binding to the Arf gene,
recruits RNA polymerase II, and then increases Arf mRNA and
protein expression (Freeman-Anderson et al., 2009; Zheng et al.,
2010). Interestingly, even though we isolated the PVCs by virtue
of Tgfb2-driven Arf promoter activation and Gfp expression, addi-
tion of Tgfb1 (5 ng/ml) further increased Gfp mRNA expression in
these cells ex vivo (Fig. 1B). Hence, the developmental signaling
pathway that is critical for eye development is maintained in
cultured PVCs. This ﬁnding is also consistent with our previous
global gene expression analysis showing that components of the
Tgfb pathway deﬁned as being important for Arf induction, such as
Smad2/3, Sp1 and Cebpb, are expressed in PVCs (Iqbal et al., 2014b).
As highlighted above, p19Arf inhibits cell proliferation and, in the
context of eye development, it speciﬁcally blunts mitogenic effects
of PDGF-B by down-regulating the expression of Pdgfrb (Silva et al.,
2005). To test whether p19Arf similarly arrests cultured PVCs, we
utilized propidium iodide staining followed by ﬂow cytometry and
quantiﬁcation using the Watson Pragmatic Model Watson 1987
(Watson et al., 1987). We generated MSCV-based retroviral vectors
containing Arf cDNA upstream of an IRES element driving expres-
sion of Rfp (Iqbal et al., 2014b). Transducing PVCs with the Arf-IRES-
RFP vector signiﬁcantly decreased the fraction of cells in S-phase
with an accumulation of cells in G1 and G2 phases as compared to
the Rfp control (Fig. 2A). Of note, it is not currently possible to study
the effect of endogenous Arf expression in PVCs for several reasons.
First, p19Arf expression from the wild type allele in an ArfGfp/þ
Fig. 2. p19Arf inhibits PDGF-B driven proliferation in the PVCs. A) Quantiﬁcation of DNA content of PVCs as detected by propidium iodide and ﬂow cytometry. PVCs were transduced
with MSCV-Rfp control or MSCV-Arf-Rfp retrovirus and harvested 48 h later. Cell cycle phases were deﬁned using the Watson Pragmatic Model. Quantiﬁcation of S-phase fraction is
shown on right. B) PVCs were transduced with MSCV-Rfp control or MSCV-Arf-Rfp. Cells were stimulated with 50 ng/mL PDGF-B for 16 h and cell cycle was analyzed as above
(* ¼ p < 0.02).
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do so ex vivo. Indeed, earlier work with Arfþ/ MEFs demonstrated
that serial expansion (which would be required if attempting to
propagate PVCs from the very small numbers in a phenotypically
normal ArfGfp/þ eye) usually results in cells that have lost the
remaining wild type allele (Zindy et al., 1998). Second, it is not yet
possible to purify ArfGfp/þ PVCs before Arf is expressed as we depend
on Gfp expression for the ﬂow cytometry sorting, and the Arf pro-
moter drives the Gfp reporter. Nonetheless, the capacity for ectopic
expression of p19Arf to mimic the in vivo arrest provides a new
opportunity for structure-function analyses of p19Arf and identiﬁ-
cation of downstream effectors in one of the very few cell types
known to normally express this protein in the developing mouse.
As mentioned above, we know that primary vitreous hyper-
plasia in the Arf/ mouse is driven by Pdgfrb (Silva et al., 2005;
Widau et al., 2012). Hence, we evaluated how PDGF-B, the ligand
for this receptor, inﬂuenced PVC proliferation and the capacity for
p19Arf to block the effects using the explanted cells. First, exposure
of serum-starved PVCs to PDGF-B (50 ng/ml) for 16 h increased the
S-phase fraction by over two fold, but ectopic expression of p19Arf
completely abrogated this effect (Fig. 2B). We correlated this
blockade with the ability for p19Arf to signiﬁcantly repress Pdgfrb
mRNA and protein (Fig. 3A and B). We conclude that ex vivo studies
of PVCs faithfully reﬂect the in vivo biology: PDGF-B drives PVC
proliferation and Arf expression blocks it by a mechanism that leads
to decreased Pdgfrb expression.
Although p19Arf is most well-known for its capacity to sequester
Mdm2 and thereby stabilize p53 (Honda and Yasuda, 1999; Weber
et al., 1999), the protein also acts independently of p53 to inhibit
ribosomal RNA processing (Sugimoto et al., 2003), associate with
E2F1 and c-Myc to inhibit their trans-activating potential (Datta
et al., 2004; Eymin et al., 2001; Qi et al., 2004) and promoteFig. 3. Pdgfrb expression in PVCs depends on p19Arf. A) Relative expression of Pdgfrb mRNA
Representative western blot showing Pdgfrb, p19Arf and HSC-70 protein expression in lysat
Western signal (on right) is quantiﬁed using the Odyssey Image Studio Lite system and nosumoylation of Mdm2, nucleophosmin and other proteins (Rizos
et al., 2005; Tago et al., 2005). Genetic evidence from mouse
studies suggests that p19Arf likely controls primary vitreous
expansion in a manner that does not strictly depend on p53. Ocular
development is normal in most strains of mice lacking p53; how-
ever, certain pure BALB/c and pure C57Bl/6 lines of p53/ mice
have a PHPV/PFV-like phenotype with variable penetrance (Ikeda
et al., 1999). Further, the developmental defect in C57Bl/6 mice is
abrogated when the animals are bred into a mixed C57Bl/6  129/
Sv background (Reichel et al., 1998). In contrast, PHPV consistently
develops in Arf/ mice in pure C57Bl/6 and pure 129/Sv lines as
well as mixed C57Bl/6  129/Sv animals (McKeller et al., 2002). We
have taken this to mean that while p53 may play a role in tran-
scriptional repression of PdgfrbmRNA, Arf expression represses the
protein through p53 independent mechanisms (Widau et al., 2012).
We utilized the PVC model to evaluate the role that p53 plays in
Arf-dependent repression of PdgfrbmRNA and protein. Because our
PVCs retain the p53 gene, we developed PVC sub-lines in which
LMP-based retroviral vectors (obtained from S. Lowe, Memorial
Sloan Kettering Cancer Center) delivered either control or p53-
speciﬁc shRNA, and puromycin was used to select pools of PVCs
retaining p53 (shCTL) and those with p53 knockdown (shp53).
Although not complete, the knockdown is functionally signiﬁcant:
ectopic expression of Arf in the shCTL cells robustly increases p53
(Fig. 5B, lanes 1 and 2), but similar transduction of Arf into
shp53 cells only increases p53 to a level that is still lower than
baseline in the control cells (Fig. 5B, compare lanes 2 and 4). As
another functional measure, doxorubicin (Dox) augments the
expression of p21Cip1, a well-known p53 target (Harper et al.,
1993), in a dose-dependent manner; this effect is also dramati-
cally decreased in the p53 knockdown PVCs (Fig. 4A). We also
observed that the baseline S phase fractionwas slightly increased inas measured by qRT-PCR upon transduction with MSCV-Rfp control or MSCV-Arf-Rfp. B)
es prepared from PVCs transduced with MSCV-Arf-Rfp retrovirus or MSCV-Rfp control.
rmalized to Hsc-70 (* ¼ p < 0.05).
Fig. 4. p19Arf inhibits PDGF-B driven proliferation independently of p53. A) Representative western blot showing p53 induction in response to doxorubicin (Dox) treatment. p53 and
p21 are induced upon treatment in shCTL cells but not shp53 cells. Quantiﬁcation, normalized to Hsc-70, is on right. B) Quantiﬁcation of percent of cells in S-phase as measured by
propidium iodide and ﬂow cytometry. shCTL or shp53 PVCs were transduced withMSCV-Rfp control orMSCV-Arf-Rfp and stimulated with 50 ng/mL PDGF-B for 16 h. C) Fold change
of S-phase fraction of cells in response to PDGF-B (* ¼ p < 0.05).
Fig. 5. p53-dependent effects of p19Arf on Pdgfrb and miR34a. A) qRT-PCR showing relative expression of Pdgfrb mRNA upon transduction with MSCV-Rfp control or MSCV-Arf-Rfp
retrovirus in shCTL or shp53 cells. B) Representative western blot showing Pdgfrb, p53, p19Arf and Hsc-70 protein expression in lysates prepared from shCTL or shp53 cells
transduced with MSCV-Rfp control or MSCV-Arf-Rfp retrovirus. Western signal (on right) is quantiﬁed using the Odyssey Image Studio Lite system and normalized to Hsc-70. C)
Relative expression of primary-miR34a transcript in response to ectopic p19Arf expression in shCTL and shp53 cells. D) Relative expression of mature miR34a in response to ectopic
p19Arf expression in shCTL and shp53 cells. miR34a is normalized to U6 (* ¼ p < 0.05).
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exogenous PDGF-B drove additional cells into S phase (Fig. 4B, lanes
1 vs 2 and 5 vs 6). Importantly, ectopic Arf expression blunted themitogenic effects of PDGF-B in the presence and in the absence of
p53 knockdown (Fig. 4B, lanes 2 vs 4 and 6 vs 8, and Fig. 4C).
We used this system to address the importance of p53 in two
N.S. Iqbal et al. / Experimental Eye Research 145 (2016) 224e229228Arf-dependent responses: PdgfrbmRNA and protein repression and
miR34a induction. First, as with the parental PVCs (Fig. 3A), ectopic
Arf expression signiﬁcantly decreased Pdgfrb mRNA but this effect
was completely negated when p53 was knocked down (Fig. 5A). In
contrast, Arf expression still retained the capacity to repress Pdgfrb
protein in shp53 PVCs, though the effect was somewhat moderated
(Fig. 5B). In a similar way, Arf can increase the expression of primary
miR34a, but only in the presence of p53 (Fig. 5C), but p53 is at least
partly dispensable for induction of mature miR34a e indicating a
p53-independent role for p19Arf in processing of this microRNA
(Fig. 5D). All of these molecular effects are similar to those that we
observed in vivo during primary vitreous development and matu-
ration (Martin et al., 2004; Silva et al., 2005; Widau et al., 2012).
3. Discussion
In the mouse, the mature testis, developing eye, and umbilical
arteries are the only sites where numerous Arf expressing cells are
normally found (Freeman-Anderson et al., 2009; Silva et al., 2005;
Zindy et al., 2003). Arf expressing cells in the eye include those
perivascular cells embracing the hyaloid artery and also cells scat-
tered in the cornea (Silva et al., 2005; Thornton et al., 2007; Zindy
et al., 2003). Primary vitreous hyperplasia is the only recognized
developmental defect due to Arf gene inactivation (Martin et al.,
2004; McKeller et al., 2002), and this ocular disease is due to
Pdgfrb-driven proliferation in the aforementioned perivascular
cells (Silva et al., 2005; Widau et al., 2012). Because the PVCs are
unique as the only cell type known to be altered without Arf, it was
important to validate the functional and biochemical effects of
p19Arf in these cells. Indeed, using this new ex vivomodel, we have
established the following: 1) The Arf promoter can be engaged by
Tgfb to induce Arf expression in PVCs ex vivo; 2) Ectopic Arf
expression arrests PVC proliferation, including proliferation driven
by PDGF-B; 3) Cell proliferation arrest by p19Arf correlates with
repression of Pdgfrb; 4) and Arf expression in PVCs checks prolif-
eration, decreases Pdgfrb protein, and induces mature miR-34a
independently of p53. All of these new ﬁndings accurately reﬂect
the in vivo effects of p19Arf during eye development.
Since the Arf cDNA was ﬁrst cloned, most of the cell-based
functional studies have been carried out in MEFs, a wide range of
ﬁbroblast cell lines, and cancer cell lines e none of which reﬂect a
“normal” cellular context. Despite that inherent limitation, much
has been gleaned from such studies. Indeed, our own laboratory has
deﬁned most of the aforementioned molecular and cell biological
effects of p19Arf in MEFs and 10T1/2 ﬁbroblasts (Silva et al., 2005;
Weber et al., 2000). However, a more granular understanding of
Arf biology is likely to depend on context e expressing the protein
in the right cell type. Gaining a better understanding of the nature
of the perivascular cells and how Arf inﬂuences their biology rep-
resents one such area. These particular PVCs are nearly unique for
two reasons. First, they embrace blood vessels that undergo dra-
matic regression in the immediate postnatal period. Second, they
are the only cells in the eye that express p19Arf. We state they are
“nearly” unique because the umbilical arteries branching from the
internal iliac vessels represent another vascular system that be-
comes superﬂuous in the immediate postnatal period, and this is
the only other vasculature enveloped by Arf expressing perivascular
cells (Freeman-Anderson et al., 2009). Of note, we have not yet
uncovered a defect in the umbilical vessels when p19Arf is absent.
Nearly all work on Arf in the eye has focused on how it controls the
number of these PVCs e essentially, how it blocks primary vitreous
hyperplasia. Yet, the fact that Arf is expressed in the cells from E11.5,
just as the hyaloid vessels are forming (Silva et al., 2005), and the
expression is extinguished at P5, just as the vessels begin to regress
(Mitchell et al., 1998), suggests another role for p19Arf: it mightactually be required to temporarily stabilize the otherwise transient
vessels. Perivascular cells, especially pericytes that represent a
particular type of vascular mural cell, provide trophic signals to
underlying endothelial cells (Hanahan and Folkman, 1996;
Yancopoulos et al., 2000). Having developed an ex vivo culture
model for those PVCs, we are only now in a position to establish
more sophisticated systems to study these potential heterotypic
interactions with endothelial cells and the role that p19Arf may play.
Similar comments can be made about the emerging role that
p19Arf can play as amicroRNA regulator.We previously showed that
this protein can increase the expression of miR-34a independently
of p53 pathway, and miR34a is needed for post-transcriptional
Pdgfrb repression and p53-independent cell proliferation control
(Iqbal et al., 2014a). Others have shown e using MEFs e that p19Arf
physically interacts with Drosha, and this interaction both increases
and decreases the expression of a wide range of microRNAs
(Kuchenreuther and Weber, 2014). We do not yet understand the
mechanism by which p19Arf can induce miR-34a independently of
p53, nor do we know the full spectrum of microRNA changes that
accompany Arf expression in PVCs that normally express the pro-
tein. Because both of these are likely to be cell context-dependent,
conducting the work in PVCs may provide the correct perspective
for such studies. Ultimately, these types of analyses may inform our
understanding of PHPV/PFV pathogenesis.4. Methods
4.1. Cell isolation and culture
PVCs were isolated from early post-natal ArfGfp/Gfp mice. Method
for isolation is described in detail in Iqbal et al. (2014b). PVCs were
cultured in Pericyte Medium (PM) (ScienCell) and passaged using
trypsin/EDTA. Tgfb1 (R&D Systems), was added to cell culture
medium at a dose of 5 ng/ml; an equivalent volume of vehicle
(4 mM HCl) was added into the medium as a control. PVCs were
transduced with MSCV-RFP or MSCV-Arf-RFP retrovirus. 16 h post
transduction, culture media was replaced. 50 ng/mL PDGF-B was
added to the cells for 16 h prior to harvesting for cell cycle analysis.4.2. RNA expression
Total RNA was extracted from PVCs with miRNeasy mini kit
(Qiagen). For qRT-PCR, 1 mg of total RNA was reverse transcribed
using Superscript III RT kit (Invitrogen) according to the manufac-
turer's recommendations. Quantitative RT-PCR (qRT-PCR) was
performed with KAPA SYBR Green Mastermix (KAPA) on BioRad
(CFX96). The PCR program consisted of 20 s at 95 C, followed by 40
cycles of 95 C for 15 s and 60 C for 20 s. Primer quality was
analyzed by dissociation curves. The expression of Pdgfrb and pri-
miR34a was normalized to Gapdh. miR-34a was normalized to U6.4.3. Cell cycle analysis
Propidium Iodide (PI) (Sigma) staining was performed after cells
were harvested by trypsin-EDTA and ﬁxed in 70% ethanol. Fixed
cells were washed in PBS and centrifuged at 1200 rpm for 5 min.
Cells were resuspended in 0.3 ml PBS and RNaseA (Sigma) was
added to the suspension to ﬁnal concentration of 0.5 mg/ml. After
1 h of incubation at 37 C, PI was added to the suspension to a ﬁnal
concentration of 10 mg/ml. PI-stained cells were analyzed for DNA
content with a BD Calibur ﬂow cytometer and Watson Pragmatic
Model to calculate the distribution of cells in G1, S, and G2 cell cycle
phases. Results are averaged from 3 biological replicates.
N.S. Iqbal et al. / Experimental Eye Research 145 (2016) 224e229 2294.4. Western blot
Protein expression was examined by Western-blotting accord-
ing to a standard procedure. The following antibodies were used:
anti-p19Arf (Ab80, Abcam, 1:1000), anti-Pdgfrb (AF1042, R&D,
1:1000), anti-Hsc70 (Sc-1059, Santa Cruz, 1:5000), anti-p53 (Sc-
6243, Santa Cruz, 1:1000). Band intensity was quantiﬁed using the
Odyssey Image Studio Lite system and normalized to Hsc-70. Re-
sults are averaged from 3 biological replicates.
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